CA2060489C - Diagnostic et traitement de troubles neuro-cognitifs associes a des troubles immunologiques generalises - Google Patents

Diagnostic et traitement de troubles neuro-cognitifs associes a des troubles immunologiques generalises Download PDF

Info

Publication number: CA2060489C
Authority: CA; Canada
Prior art keywords: dsrna; patient; use according; patients; pathway
Prior art date: 1992-01-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 2060489

Other languages

English (en)

Other versions

CA2060489A1 (fr

Inventor

William A. Carter

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hem Research Inc

Original Assignee

Hem Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-31

Filing date

1992-01-31

Publication date

2003-07-29

1992-01-31 Application filed by Hem Research Inc filed Critical Hem Research Inc

1992-01-31 Priority to CA 2060489 priority Critical patent/CA2060489C/fr

1993-08-01 Publication of CA2060489A1 publication Critical patent/CA2060489A1/fr

2003-07-29 Application granted granted Critical

2003-07-29 Publication of CA2060489C publication Critical patent/CA2060489C/fr

2012-01-31 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

230000001900 immune effect Effects 0.000 title claims abstract description 13
208000027626 Neurocognitive disease Diseases 0.000 title claims abstract description 10
230000007257 malfunction Effects 0.000 title claims abstract description 5
230000009885 systemic effect Effects 0.000 title claims abstract description 5
238000003745 diagnosis Methods 0.000 title description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 55
102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 54
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
230000037361 pathway Effects 0.000 claims description 43
230000001684 chronic effect Effects 0.000 claims description 23
208000012902 Nervous system disease Diseases 0.000 claims description 15
210000004976 peripheral blood cell Anatomy 0.000 claims description 12
102000003960 Ligases Human genes 0.000 claims description 9
108090000364 Ligases Proteins 0.000 claims description 9
230000002255 enzymatic effect Effects 0.000 claims description 9
230000001771 impaired effect Effects 0.000 claims description 9
230000003920 cognitive function Effects 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
208000000044 Amnesia Diseases 0.000 claims description 6
208000026139 Memory disease Diseases 0.000 claims description 6
230000006984 memory degeneration Effects 0.000 claims description 6
208000023060 memory loss Diseases 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
208000024827 Alzheimer disease Diseases 0.000 claims description 3
230000001594 aberrant effect Effects 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
230000003834 intracellular effect Effects 0.000 claims description 2
230000008337 systemic blood flow Effects 0.000 claims description 2
230000004075 alteration Effects 0.000 claims 8
108091034057 RNA (poly(A)) Proteins 0.000 claims 2
ZLCVZNYCKZFEIA-UHFFFAOYSA-N guanidine;1h-pyrimidine-2,4-dione Chemical compound NC(N)=N.O=C1C=CNC(=O)N1 ZLCVZNYCKZFEIA-UHFFFAOYSA-N 0.000 claims 2
239000000203 mixture Substances 0.000 claims 2
210000005259 peripheral blood Anatomy 0.000 claims 1
239000011886 peripheral blood Substances 0.000 claims 1
208000024891 symptom Diseases 0.000 abstract description 6
230000001225 therapeutic effect Effects 0.000 abstract description 3
230000006872 improvement Effects 0.000 description 31
241000700605 Viruses Species 0.000 description 29
102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 25
108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 25
102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 23
108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 23
238000012360 testing method Methods 0.000 description 22
238000002560 therapeutic procedure Methods 0.000 description 21
206010012289 Dementia Diseases 0.000 description 18
210000004027 cell Anatomy 0.000 description 17
230000000694 effects Effects 0.000 description 15
230000000840 anti-viral effect Effects 0.000 description 14
230000015654 memory Effects 0.000 description 14
210000004369 blood Anatomy 0.000 description 11
239000008280 blood Substances 0.000 description 11
238000002595 magnetic resonance imaging Methods 0.000 description 11
230000000975 bioactive effect Effects 0.000 description 10
230000009467 reduction Effects 0.000 description 9
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
230000009385 viral infection Effects 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
108091034117 Oligonucleotide Proteins 0.000 description 7
230000005856 abnormality Effects 0.000 description 7
230000036765 blood level Effects 0.000 description 7
238000001802 infusion Methods 0.000 description 7
230000003902 lesion Effects 0.000 description 7
241001430294 unidentified retrovirus Species 0.000 description 7
241000701027 Human herpesvirus 6 Species 0.000 description 6
239000000523 sample Substances 0.000 description 6
230000000007 visual effect Effects 0.000 description 6
230000001755 vocal effect Effects 0.000 description 6
208000036142 Viral infection Diseases 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
230000004913 activation Effects 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000006735 deficit Effects 0.000 description 5
230000003111 delayed effect Effects 0.000 description 5
230000006870 function Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
210000000822 natural killer cell Anatomy 0.000 description 5
208000030507 AIDS Diseases 0.000 description 4
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
239000000284 extract Substances 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
108020004418 ribosomal RNA Proteins 0.000 description 4
241001529453 unidentified herpesvirus Species 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000002490 cerebral effect Effects 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
230000007547 defect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000009483 enzymatic pathway Effects 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000007017 scission Effects 0.000 description 3
230000006403 short-term memory Effects 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
208000016192 Demyelinating disease Diseases 0.000 description 2
206010012305 Demyelination Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
206010022004 Influenza like illness Diseases 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
208000027382 Mental deterioration Diseases 0.000 description 2
206010027374 Mental impairment Diseases 0.000 description 2
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
230000003915 cell function Effects 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
230000007278 cognition impairment Effects 0.000 description 2
230000003930 cognitive ability Effects 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
231100000870 cognitive problem Toxicity 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000007123 defense Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
229920000140 heteropolymer Polymers 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
230000008450 motivation Effects 0.000 description 2
230000007106 neurocognition Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000013610 patient sample Substances 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000405 serological effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
210000004885 white matter Anatomy 0.000 description 2
108020004463 18S ribosomal RNA Proteins 0.000 description 1
206010001513 AIDS related complex Diseases 0.000 description 1
208000035657 Abasia Diseases 0.000 description 1
208000019581 Abnormal cellular phenotype Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006500 Brucellosis Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
208000026097 Factitious disease Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010019973 Herpes virus infection Diseases 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
206010061285 Mental disorder due to a general medical condition Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100248652 Mus musculus Rinl gene Proteins 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
230000007022 RNA scission Effects 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000005860 defense response to virus Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000002542 deteriorative effect Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000012953 feeding on blood of other organism Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000037417 hyperactivation Effects 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
201000006747 infectious mononucleosis Diseases 0.000 description 1
235000013902 inosinic acid Nutrition 0.000 description 1
210000002425 internal capsule Anatomy 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
229960000681 leflunomide Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
230000003923 mental ability Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000007971 neurological deficit Effects 0.000 description 1
230000007979 neuropsychological functioning Effects 0.000 description 1
238000010855 neuropsychological testing Methods 0.000 description 1
238000010606 normalization Methods 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000036284 oxygen consumption Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
208000026881 post-infectious disease Diseases 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000010079 rubber tapping Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000002739 subcortical effect Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012549 training Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
239000013638 trimer Substances 0.000 description 1
230000006496 vascular abnormality Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 2060489 1992-01-31 1992-01-31 Diagnostic et traitement de troubles neuro-cognitifs associes a des troubles immunologiques generalises Expired - Fee Related CA2060489C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2060489 CA2060489C (fr)	1992-01-31	1992-01-31	Diagnostic et traitement de troubles neuro-cognitifs associes a des troubles immunologiques generalises

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2060489 CA2060489C (fr)	1992-01-31	1992-01-31	Diagnostic et traitement de troubles neuro-cognitifs associes a des troubles immunologiques generalises

Publications (2)

Publication Number	Publication Date
CA2060489A1 CA2060489A1 (fr)	1993-08-01
CA2060489C true CA2060489C (fr)	2003-07-29

Family

ID=4149194

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2060489 Expired - Fee Related CA2060489C (fr)	1992-01-31	1992-01-31	Diagnostic et traitement de troubles neuro-cognitifs associes a des troubles immunologiques generalises

Country Status (1)

Country	Link
CA (1)	CA2060489C (fr)

1992
- 1992-01-31 CA CA 2060489 patent/CA2060489C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2060489A1 (fr)	1993-08-01

Legal Events

Date	Code	Title	Description
1999-01-19	EEER	Examination request
2011-01-31	MKLA	Lapsed

Publication	Publication Date	Title
US5258369A (en)	1993-11-02	Treatment of chronic cerebral dysfunction by dsRNA methodology
Leonardi et al.	2006	Th1-and Th2-type cytokines in chronic ocular allergy
Mintz et al.	1989	Elevated serum levels of tumor necrosis factor are associated with progressive encephalopathy in children with acquired immunodeficiency syndrome
DE69533697T2 (de)	2006-02-09	ANTISENSE OLIGONUKLEOTIDMODULATION DER raf GENEXPRESSION
Poloni et al.	2000	Circulating levels of tumour necrosis factor-α and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis
Steinberg et al.	1988	Persistence and expression of human papillomavirus during interferon therapy
JP2001500471A (ja)	2001-01-16	プロテアーゼインヒビターの生物学的及び抗ウイルス活性を改善する方法
US5958718A (en)	1999-09-28	Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
JP3208138B2 (ja)	2001-09-10	ウイルス性肝炎の診断及び治療
EP0350151B1 (fr)	1994-03-30	Diagnostic et traitement du syndrome de la fatigue chronique
Parsons et al.	1998	Diagnosis of spinal muscular atrophy in an SMN non-deletion patient using a quantitative PCR screen and mutation analysis.
RU1836101C (ru)	1993-08-23	Способ вы влени вируса человеческого иммунодефицита у животного и человека
CA2060489C (fr)	2003-07-29	Diagnostic et traitement de troubles neuro-cognitifs associes a des troubles immunologiques generalises
Strayer et al.	1995	Long term improvements in patients with chronic fatigue syndrome treated with Ampligen
De Sole et al.	1990	Lack of adverse reactions in ivermectin treatment of onchocerciasis
EP0733640A1 (fr)	1996-09-25	Oligonucleotide bicatenaire et agent carcinostatique le contenant en tant que constituant actif
WO1991000097A1 (fr)	1991-01-10	Diagnostic et traitement des infections virales associees a la fatigue chronique
Li et al.	2001	Glatiramer acetate blocks interleukin-1-dependent nuclear factor-κB activation and RANTES expression in human U-251 MG astroglial cells
US5599917A (en)	1997-02-04	Inhibition of interferon-γ with oligonucleotides
Wang et al.	2025	Identification and validation of Atp5f1c in CD4+ T cell as a hub protein in Parkinson's disease
Safai et al.	1979	A novel lymphocyte differentiating factor in serum of patients with mycosis fungoides and Sezary syndrome
CN114990204B (zh)	2025-08-26	一种trex1基因变异引起的疾病的治疗靶点及其应用
RU2257915C2 (ru)	2005-08-10	Способ лечения обострений рассеянного склероза
JP2002514999A (ja)	2002-05-21	ｄｓＲＮＡを用いてＩＬ−１を中和する方法
CN121754672A (zh)	2026-03-31	Treg程序性坏死型自身免疫性疾病的治疗方法